SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bajaj Healthcare Ltd (BAJAJHCARE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539872 NSE: BAJAJHCARE Pharmaceuticals & Drugs | Small Cap | Bajaj Healthcare Share Price

₹294.50 2.55 (0.87%)

As on 10-Jun'26 12:10

Bajaj Healthcare Ltd (BAJAJHCARE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539872 NSE: BAJAJHCARE Pharmaceuticals & Drugs | Small Cap | Bajaj Healthcare Share Price

₹294.50 2.55 (0.87%)

As on 10-Jun'26 12:10

Key Metrics
Valuation Multiples
Market Cap
₹983 Cr.
Current Price
₹294.5
52-Week Low / High
₹272 / 553
TTM EPS
₹6.3
TTM Sales
₹611 Cr.
Book Value per Share
₹158.3
P/E Ratio
46.12
Higher than its 5-year historical median
Industry PE
47
Price to Book (P/B)
1.84
Lower than its 5-year historical median
Price to Sales (P/S)
1.61
Lower than its 5-year historical median
EV/EBITDA
10.52
Lower than its 5-year historical median
Dividend Yield
0.15%
Profitability Efficiency
Return on Equity (ROE)
11.81%
Outperforms industry median
Return on Capital Employed (ROCE)
11.40%
In line with industry median
Return on Assets (ROA)
5.51%
Operating Profit Margin
15.3%
Net Profit Margin
7.91%
Gross Profit Margin
13.6%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
14.61%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
8.19%
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
58.29%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹516 Cr.
Equity
₹16.8 Cr.
Face Value
₹5
All Time Low / High
₹42.50 / 744.90

Bajaj Healthcare stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Undervalued

Price Trend

Weak
Q.1 Is Bajaj Healthcare Ltd a good quality company?
Bajaj Healthcare Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Bajaj Healthcare Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Bajaj Healthcare Ltd vs industry peers?
Bajaj Healthcare Ltd revenue CAGR is 5.76%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Bajaj Healthcare Ltd?
Promoters hold 58.29% of the Bajaj Healthcare Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Bajaj Healthcare Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 21.5% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Bajaj Healthcare Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 18%14.5%18.3%19.8%19.5%35.9%20%14%1.9%11.4%-
Value Creation
Index
0.30.00.30.40.41.60.40-0.9-0.2-

Growth Parameters

Sales 200207290325410657680646473543611
Sales YoY Gr.-3.5%39.7%12.3%26.2%60.2%3.5%-5%-26.7%14.6%-
Adj EPS 3.22.356.59.42926.422.8-7.310.86.3
YoY Gr.--28.1%118.7%28.8%44.9%208.7%-9.1%-13.5%-131.9%NA-
BVPS (₹) 17.235.926.432.264.593.6119133.2100.9142158.3
Adj Net
Profit
8.76.413.917.925.98072.763-20.134.221
Cash Flow from Ops. 25.122.116.625.220.643.60.7-22.292.321.6-
Debt/CF from Ops. 3.23.45.23.24.44.2374.3-18.73.610.3-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales 11.7%5.8%-7.2%14.6%
Adj EPS 14.5%2.9%-25.6%NA
BVPS26.5%17.1%6.1%40.8%
Share Price 21.1% -3.5% 1.1% -44.4%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
10.26.813.114.816.936.724.818.1-6.29.24.2
Op. Profit
Mgn %
15.514.913.61412.520.817.717.316.115.317.2
Net Profit
Mgn %
4.33.14.85.56.312.210.79.8-4.26.33.5
Debt to
Equity
1.80.81.20.90.50.70.81.11.20.50.1
Working Cap
Days
128133124128131115173252346302156
Cash Conv.
Cycle
6769586366498914820517968

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales200207290325410657680646473543
Operating Expenses + 170176250282362521561534397460
Manufacturing Costs37374147538992727082
Material Costs106111178197263378406383255286
Employee Cost 17202225283541424457
Other Costs 109914181922372834
Operating Profit 30313943481361191117683
Operating Profit Margin (%) 15.0%14.9%13.6%13.2%11.8%20.8%17.5%17.3%16.1%15.2%
Other Income + 02217712919
Exceptional Items 00000000-440
Interest 88887813183028
Depreciation 9111111121618172828
Profit Before Tax 13142324361199078-1746
Tax 567811361815-23
Profit After Tax 88151625837164-1443
PAT Margin (%) 4.1%3.8%5.3%5.0%6.2%12.7%10.5%9.8%-3.0%7.9%
Adjusted EPS (₹)3.02.85.55.99.130.125.923.0-5.213.6
Dividend Payout Ratio (%)0%0%4.50%0%0%4.60%5.80%4.30%-19.30%7.40%

Valuation of Bajaj Healthcare - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 8999114129178258328368278449
Share Capital 7777141414141416
Reserves 8292107122164245315354265433
Debt +7466767282168243383300199
Long Term Debt31272117248066943965
Short Term Debt423955555888176289261134
Minority Interest0000000000
Trade Payables161943305769105858995
Others Liabilities 30353535263045647572
Total Liabilities 209219268267343526721899743814

Fixed Assets

Net Fixed Assets +130128127128162208270366253238
Gross Block191200210222268329402525423436
Accumulated Depreciation62728394106121132159170198
CWIP 1021557522273
Investments 0000500000
Inventories201734303997159209144162
Trade Receivables435380789899185194180252
Cash Equivalents 018841421934
Others Assets 1521172128505490157154
Total Assets 209219268267343526721899743814

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 2522172521441-229222
PBT 13142324361199058-10442
Adjustment 171919201624315617046
Changes in Working Capital -0-6-19-6-22-64-111-12539-62
Tax Paid -5-5-6-13-9-36-10-12-13-5
Cash Flow From Investing Activity + -31-8-12-13-28-109-75-93-11-15
Capex -30-10-10-15-18-62-79-93-19-11
Net Investments 0000-55007-3
Others -01-22-4-524-01-1
Cash Flow From Financing Activity + 5-132-1337562131-97-6
Net Proceeds from Shares 0300000000
Net Proceeds from Borrowing 9-5-5-4656-1245-2426
Interest Paid -8-8-8-8-6-8-13-23-42-28
Dividend Paid 000-10-2-1-4-3-3
Others 3-315043088113-28-2
Net Cash Flow -007-0-410-1216-160

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)19.610.7717.6820.1818.9238.0924.3318.25-4.4411.81
ROCE (%)1814.5218.2519.7519.4735.912014.021.8811.4
Asset Turnover Ratio1.121.081.341.381.341.511.090.80.580.7
PAT to CFO Conversion(x)3.132.751.131.560.840.530.01-0.34N/A0.51
Working Capital Days
Receivable Days77.4075.7074.2078.2078.6054.8076.10107144.30145.30
Inventory Days30.9028.8028.1031.4030.9037.9068.80104136102.90
Payable Days67.2057.5063.906860.6061.1078.1090.40124.80117.80

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Bajaj Healthcare Ltd FAQs

The current trading price of Bajaj Healthcare on 10-Jun-2026 12:10 is ₹294.5.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 09-Jun-2026 the market cap of Bajaj Healthcare stood at ₹982.8 Cr

The latest P/E ratio of Bajaj Healthcare as of 09-Jun-2026 is 46.12.

The latest P/B ratio of Bajaj Healthcare as of 09-Jun-2026 is 1.84.

The 52-week high of Bajaj Healthcare is ₹552.5 and the 52-week low is ₹272.4.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bajaj Healthcare is ₹611 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Bajaj Healthcare Ltd is a good quality company.

The key valuation ratios of Bajaj Healthcare Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bajaj Healthcare Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Bajaj Healthcare Ltd

The company was incorporated as Bajaj Healthcare Private Limited on July 15, 1993 under the Companies Act, 1956, with the Registrar of Companies, Mumbai bearing Registration Number - 072892. The status of the company was changed to a public limited company and the name of the company was changed to Bajaj Healthcare Limited by a special resolution passed on March 15, 2005. A fresh certificate of incorporation consequent to the change of name was granted to the company on March 31, 2005, by the Registrar of Companies, Mumbai. The company began its operations in the year 1993 with an API manufacturing unit in Tarapur, near Mumbai. Over the years it has expanded its scale and scope of operations and currently it operates five manufacturing units for manufacture of APIs, Intermediates and Formulations.

The company’s present product portfolio consists of various APIs in the therapeutic categories of Neutraceutical (Amino Acids), Vitamins, Anti-Convulsants, Bactericidal & Bacteriostatic, Diuretic & Vasodilator, Mineral & Nutritional supplements, Bronchodilater / Anti-asthmatic and Nootropics. The company’s Formulations unit manufactures tablets, capsules and sachets for its own brands as well as under Loan License (job work) for other pharmaceutical companies. Currently, the company manufactures formulations for GlaxoSmithKline Pharmaceuticals (GSK) and USV (USV) on a Loan License basis. The formulations manufactured for its own brands are manufactured and marketed under a separate division of Bajaj Medicare and it also has marketing tie-up with TTK Healthcare. The FDFs manufactured by it covers various therapeutic segments like Antibiotics, Anti-Arrhythmia, Anti-Convulsants, Anti-Diabetes, Anti-Platelets, NSAIDs, Vitamins & its Derivatives, Anti-Hypertensive, Anti-Bacterial, Anti-Malarial, Cholinesterase Inhibitors, etc.

With the combined production of its API facilities and that of its Formulation unit, the company’s product portfolio consists of APIs and FDFs which shall be marketed in domestic and international markets as branded generics. Presently it is supplying its APIs and FDFs both domestically and exporting to various countries in regions like, Europe, USA, Australia, Africa, South America, etc. With its long standing operations and quality products, the company has built a strong relationship with its customers for both APIs and FDFs. Some of its major clients include nationally and internationally known pharmaceutical companies like Glaxo Smithkline Consumer Healthcare, Ava Inc., Abbott Healthcare, Piramal Enterprises, Pfizer, Colgate Palmolive India, Lupin and Intas Pharmaceuticals to name a few.

Business area of the company

Bajaj Healthcare is a pharmaceutical company with manufacturing and marketing capabilities in Active Pharmaceutical Ingredients (APIs), Intermediates and Finished Dosage Formulations (FDFs) with focus on Vitamins, Amino Acids, Anti-Convulsants and Finished Dosage Forms (FDFs) caters to various therapeutic segments.

Major events

  • 1993-1994: Incorporated under Companies Act, 1956 as Bajaj Healthcare Private Limited by setting up plant at Tarapur.
  • 1996-1997: First Export Sale.
  • 2004-2005: Changed the status of the company from Private to Public i.e. to Bajaj Healthcare Limited.
  • 2005-2006: Purchase and Set-up a new facility at Salvi, Vadodara.
  • 2005-2006: Set up Corporate Office in Masjid Bunder.
  • 2006-2007: Purchase addition Plot N- 128 at Tarapur.
  • 2006-2007: Issued 20,00,000, Non- Cumulative Preference Shares of Rs 10 each.
  • 2006-2007: Major Term loan of Rs 863.00 lakhs was sanction and its total indebtedness reached to Rs 2,265 Lakh.
  • 2007-2008 Purchase and Set-up a new facility at Manjusar, Vadodara.
  • 2007-2008 Increase in Capacity of its major products like; 100% Vitamin C and its derivatives and 50% in Choline Bitartrate, etc.
  • 2009-2010: Launched own brands under Manjusar/ Medicare.
  • 2013-2014: Purchase and Set-up a new facility at Panoli, Ankleshwar.
  • 2013-2014: First GVK Agreement.
  • 2013-2014: First USV Agreement.
  • 2014-2015: Purchase and Set-up a Second facility at Tarapur, Maharashtra.
  • 2015-2016: Acquisition of premises for new Corporate Office in Thane and set-up of the same.
You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×